Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3969
Name thyroid gland papillary carcinoma
Definition A differentiated thyroid gland carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer abd arises from the follicular cells of the thyroid gland.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid gland cancer thyroid gland carcinoma thyroid gland adenocarcinoma differentiated thyroid gland carcinoma thyroid gland papillary carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Ramucirumab thyroid gland papillary carcinoma not applicable detail...
RET rearrange Sorafenib thyroid gland papillary carcinoma sensitive detail...
RET rearrange Ponatinib thyroid gland papillary carcinoma sensitive detail...
PIK3CA E542K MK2206 thyroid gland papillary carcinoma sensitive detail...
PIK3CA E542K MK2206 + Temsirolimus thyroid gland papillary carcinoma sensitive detail...
BRAF V600E RO5126766 thyroid gland papillary carcinoma sensitive detail...
Unknown unknown Lenvatinib thyroid gland papillary carcinoma not applicable detail...
RET fusion Selpercatinib thyroid gland papillary carcinoma sensitive detail...
BRAF act mut Vemurafenib thyroid gland papillary carcinoma sensitive detail...
BRAF V600E Dabrafenib + Trametinib thyroid gland papillary carcinoma predicted - sensitive detail...
EML4 - NTRK3 Entrectinib thyroid gland papillary carcinoma predicted - sensitive detail...
RET fusion Pralsetinib thyroid gland papillary carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00770263 Phase I Erlotinib + Temsirolimus Erlotinib and Temsirolimus for Solid Tumors Completed
NCT01534897 Phase I Dabrafenib Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 Completed
NCT01677741 Phase I Dabrafenib A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects Active, not recruiting
NCT01709292 Phase II Vemurafenib Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer Active, not recruiting
NCT01723202 Phase II Dabrafenib + Trametinib Dabrafenib Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting
NCT02145143 Phase 0 Vemurafenib Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study Active, not recruiting
NCT02211222 Phase I Lenvatinib An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer Approved for marketing
NCT02702388 Phase II Lenvatinib Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile Active, not recruiting
NCT02973997 Phase II Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT03002623 Phase II CUDC-907 CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer Terminated
NCT03215095 Phase I Durvalumab RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers Active, not recruiting
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Recruiting
NCT03469011 Phase I Imatinib A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. Recruiting
NCT03914300 Phase II Cabozantinib + Ipilimumab + Nivolumab Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer Recruiting
NCT04321954 Phase II Lenvatinib Lenvatinib in Locally Advanced Invasive Thyroid Cancer Not yet recruiting
NCT04462471 Phase I Copanlisib + Vemurafenib Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Recruiting